Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02143635
Title Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

acute lymphoblastic leukemia

Advanced Solid Tumor

Therapies

Siremadlin

Age Groups: adult
Covered Countries USA | FRA | ESP | DEU

Additional content available in CKB BOOST